關(guān)于新興藥物的專家意見提供了最快速發(fā)展的藥物類別和治療領(lǐng)域的專家評(píng)估。由主要專家編寫的新興藥物簡(jiǎn)介是權(quán)威的、全面的和最新的。新興藥物的專家意見是必不可少的閱讀醫(yī)藥和學(xué)術(shù)科學(xué)家，研究規(guī)劃，醫(yī)藥產(chǎn)品經(jīng)理，臨床意見領(lǐng)袖和醫(yī)療保健規(guī)劃。制定關(guān)于新興藥物的專家意見的目的是對(duì)最重要的新興藥物技術(shù)提供專家評(píng)價(jià)。這些評(píng)估是根據(jù)它們對(duì)當(dāng)前特定疾病管理的潛在影響。關(guān)于新興藥物的專家意見還包括關(guān)于新興藥物發(fā)展戰(zhàn)略的論文，其目的是對(duì)最有希望的藥物研究領(lǐng)域的商業(yè)和技術(shù)可行性提供一種可獲得和獨(dú)立的評(píng)估。

Expert Opinion on Emerging Drugs provides an expert assessment of the most rapidly advancing drug classes and therapeutic areas. Emerging Drugs profiles, prepared by leading experts, are authoritative, comprehensive and up-to date. Expert Opinion on Emerging Drugs is essential reading for pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners. Expert Opinion on Emerging Drugs was devised with the intention of providing an expert evaluation of the most important emerging drug technologies. These are assessed in terms of their potential impact on the current management of specific diseases. Expert Opinion on Emerging Drugs also includes papers on Emerging Drug Development Strategies, which aim to provide an accessible and independent assessment of the commercial and technical viability of the most promising areas of drug research.